Gara Jalqabaatti › Kansara Qara'a Non-Small Cell › Florida › Deltona
Qorannoo klinikaalii Kansara Qara'a Non-Small Cell Deltona, FL keessatti
Qorannoo 15 Kansara Qara'a Non-Small Cell f Deltona fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Namoota walitti qabaa jiraSadarkaa 1/2
- Mid Florida Hematology And Oncology Center /ID# 273777, Orange City · Miili 4 fagaatti
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Namoota walitti qabaa jiraSadarkaa 3
- Mid Florida Hematology and Oncology Center ( Site 0018), Orange City · Miili 4 fagaatti
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Alpha Clinical Research Centers LLC, Orange City · Miili 4 fagaatti
- Florida Cancer Specialists, Orange City · Miili 4 fagaatti
- Mid Florida Hematology and Oncology Center, Orange City · Miili 4 fagaatti
- fi 1 dabalataa
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Namoota walitti qabaa jiraSadarkaa 3
- Mid Florida Hematology and Oncology Center, Orange City · Miili 4 fagaatti
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Namoota walitti qabaa jiraSadarkaa 1/2
- Mid Florida Hematology and Oncology Center, Orange City · Miili 4 fagaatti
Pan-tumor MRD Study
Namoota walitti qabaa jiraQorannoo ilaalaa
- Mid Florida Cancer Centers, Orange City · Miili 4 fagaatti
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Orange City · Miili 4 fagaatti
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Namoota walitti qabaa jiraSadarkaa 3
- Mid Florida Hematology and Oncology Center, Orange City · Miili 4 fagaatti
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Namoota walitti qabaa jiraSadarkaa 2/3
- Mid Florida Cancer Centers, Orange City · Miili 4 fagaatti
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Namoota walitti qabaa jiraSadarkaa 3
- Mid Florida Hematology and Oncology Center, Orange City · Miili 4 fagaatti
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Namoota walitti qabaa jiraSadarkaa 2/3
- Local Institution - 007-926-B, Daytona Beach · Miili 26 fagaatti
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Mid-Florida Hematology & Oncology Centers, P.A., Orange City · Miili 4 fagaatti
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Orange City · Miili 4 fagaatti
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Namoota walitti qabaa jiraSadarkaa 1/2
- Mid Florida Hematology and Oncology Center, Orange City · Miili 4 fagaatti
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Mid Florida Hematology and Oncology Center, Orange City · Miili 4 fagaatti
Qorannoo Kansara Qara'a Non-Small Cell magaalota biroo keessatti
- Houston, TXQorannoo 145
- New York City, NYQorannoo 121
- Arlington, VAQorannoo 104
- Nashville, TNQorannoo 97
- Boston, MAQorannoo 90
- Los Angeles, CAQorannoo 87
- St. Louis, MOQorannoo 73
- Chicago, ILQorannoo 61
- Baltimore, MDQorannoo 60
- San Antonio, TXQorannoo 59
- Columbus, OHQorannoo 57
- Washington, DCQorannoo 55
Qorannoo biroo Deltona keessatti
- ObesityQorannoo 11
- Dhukkubaa AlzheimerQorannoo 10
- Sukkaraa Gosa 2Qorannoo 10
- Baayyee UlfaataaQorannoo 9
- Saree OljooQorannoo 8
- Dhibee QaraQorannoo 8
- Saree (Gosoota Hunda)Qorannoo 7
- Kansara MetastatikiiQorannoo 5
- COPDQorannoo 5
- Dhiibbaa Dhiigaa Ol'aanaaQorannoo 5
- MelanomaQorannoo 5
- Osteo-aartiriitii JoojiiQorannoo 5
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.